# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketPHAXIAM r...
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...
Approval of study design by French ANSM and Ethics CommitteeRecruitment of 12 patients expected to start in Q4 2023 in 4 French...